Scientist II, CRISPR-X - Gene Insertion

Crispr-Therapeutics-1; Boston (MA); On-site; USD 130,000 - 140,000; Full time

Job summary

CRISPR Therapeutics is seeking a Scientist II to grow our CRISPR-X team and advance next‑gen gene editing therapies for human disease. You will design and execute research using molecular biology, CAR T, and immune-oncology approaches, contributing to a broad clinical portfolio.

The role emphasizes hands-on development of genome editing modalities, collaboration across teams, and on-site manufacturing activities. Excellent problem solving and scientific rigor are essential.

Qualifications

• Ph.D. in biology, bioengineering, immunology, or related discipline with 2-5+ years of professional experience, or non-PhD and 10-12+ years of progressive, relevant experience.
• Experience with gene editing technologies and advancing next-generation gene editing approaches.
• Hands-on experience with CAR T cell engineering including construct design and functional characterization.

Responsibilities

• Lead, design, and optimize research exploring next-generation gene editing strategies and immunology.
• Design, execute, and interpret research using cloning, qPCR/ddPCR, NGS, RNA/DNA analysis, and cell culture.
• Guide construct design and interpretation of in-vivo CAR T and immune studies.
• Develop translational assays to evaluate gene editing and CAR approaches across in-vitro and in-vivo systems.

Skills

Gene editing

CAR T cell engineering

Molecular biology

Cloning

qPCR/ddPCR

NGS

Education

Ph.D. in biology, bioengineering, immunology, or related field

2-5+ years of professional experience (or 10-12+ for non-PhD)

Tools

qPCR

NGS

Cell culture

Job description

Company Overview

Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion‑dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene‑editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly‑owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Position Summary

Are you passionate about developing next-gen CRISPR therapies? We are seeking a highly motivated and creative Scientist II to grow our diverse, innovation‑focused CRISPR‑X team that pioneers novel gene editing therapies for human disease. We are part of CRISPR Therapeutics, a leading gene editing company with a broad clinical portfolio. The successful candidate will be an integral part of our team, whose aim is to research, develop and advance the next generation of genome editing modalities and genetic therapies for a wide range of human indications. The position requires enthusiasm, passion, outstanding skills in the art, attention to detail, and a desire to create new medicines for patients.

Responsibilities

• Lead, design, and optimize research with the aims of exploring and developing next‑generation gene editing strategies, primarily gene insertions, using CRISPR‑based tools and beyond, and synthetic immunology.


• Design, execute, and interpret research requiring molecular biology techniques including cloning, qPCR/ddPCR, NGS, RNA and DNA analysis, cell culture, and other cell‑based assays.


• Use knowledge of immune cell biology to guide construct design, target selection, and interpretation of phenotypic outcomes of in‑vivo CAR T and other immune studies.


• Dissect published literature to find novel solutions to gene editing and immunology problems.


• Develop a deep understanding of the biology underlying new disease indications and design translational assays and experimental strategies to enable evaluation of gene editing and CAR approaches across in‑vitro and in‑vivo systems.

Minimum Qualifications

• Prior experience with gene editing, including experience applying and developing next generation gene editing technologies, such as recombinases, retrotransposons or other integration approaches, in an academic and/or industry setting, with a track record demonstrating significant contributions.


• Hands‑on experience with chimeric antigen receptor (CAR) T cell engineering, including CAR construct design, gene editing and/or transgene delivery in primary human T cells, and functional characterization of the resulting CAR‑T cells.


• Ph.D. in biology, bioengineering, immunology, or related discipline with 2‑5+ years of professional experience, or non‑PhD and 10‑12+ years of progressive, relevant experience.


• Outstanding problem‑solving skills and attitude to think outside the box.


• Excellent writing, reviewing, and presentation skills.


• Challenges oneself continuously to enhance scientific capabilities.


• Ability to work independently as well as collaboratively in a results‑oriented research team environment.


• Must possess critical thinking and self‑reliance to solve tasks independently.


• Self‑motivated and scientifically rigorous, with outstanding organization and multitasking capability.


• Entrepreneurial spirit showing resourcefulness, accountability, agility to pivot, transparency, and productivity.

Preferred Qualifications

• Prior experience with protein and/or RNA engineering.


• Prior experience establishing next‑generation CAR T cells ex‑vivo and/or in‑vivo CAR T cells.


• Prior experience with diverse delivery technologies, including transfection/nucleofection, lipid nanoparticles, and viral vectors/particles.


• Prior experience designing and executing in vivo studies, including downstream tissue processing.


• Experience managing and mentoring junior scientists.

Competencies

• Collaborative – Openness, One Team


• Undaunted – Fearless, Can‑do attitude


• Results Orientation – Delivering progress toward our mission.


• Sense of urgency in solving problems.


• Entrepreneurial Spirit – Proactive.


• Ownership mindset.

Due to the nature of their work, our manufacturing and lab‑based positions are located fully on‑site.

Scientist II: Base pay range of $130,000 to $140,000+ bonus, equity and benefits. The range provided is CRISPR Therapeutics’ reasonable estimate of the base compensation for this role. The actual amount will be based on job‑related and non‑discriminatory factors such as experience, training, skills, and abilities.

CRISPR Therapeutics, Inc. is committed to equal employment opportunity and non‑discrimination for all employees and qualified applicants without regard to a person's race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law.

To view our Privacy Statement, please click the following link: http://www.crisprtx.com/about‑us/privacy-policy

Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research‑stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize‑winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines.

To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Vertex Pharmaceuticals.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly‑owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.

CRISPR Therapeutics, Inc. is committed to equal employment opportunity and non‑discrimination for all employees and qualified applicants without regard to a person's race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law.

To view our Privacy Statement, please click the following link: http://www.crisprtx.com/about‑us/privacy-policy